Compare BEAT & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAT | KZR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 54.2M |
| IPO Year | N/A | 2018 |
| Metric | BEAT | KZR |
|---|---|---|
| Price | $0.88 | $7.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $5.63 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 610.9K | 118.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $3.53 |
| 52 Week High | $4.00 | $7.55 |
| Indicator | BEAT | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 54.64 |
| Support Level | $0.81 | $7.25 |
| Resistance Level | $1.28 | $7.47 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 5.62 | 37.50 |
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.